Drew M. Pardoll
53Patents
21h-index
76Co-inventors
91Inventor score
Filing activity: Jan 22, 1993 → Sep 26, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5637483A | Irradiated tumor cell vaccine engineered to express GM-CSF | Chemistry; Metallurgy | 81 | Expired |
| US6268411A | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses | Chemistry; Metallurgy | 64 | Expired |
| US5861159A | Controlled release of pharmaceutically active substances for immunotherapy | Emerging Cross-Sectional Technologies | 63 | Expired |
| US5633234A | Lysosomal targeting of immunogens | Emerging Cross-Sectional Technologies | 61 | Expired |
| US5904920A | Regulation of systemic immune responses utilizing cytokines and antigens | Chemistry; Metallurgy | 58 | Expired |
| US9132281B2 | Focused radiation for augmenting immune-based therapies against neoplasms | Human Necessities | 56 | Active |
| US7767202B2 | Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules | Emerging Cross-Sectional Technologies | 44 | Expired |
| US6193970A | Controlled release of pharmaceutically active substances for immunotherapy | Emerging Cross-Sectional Technologies | 43 | Expired |
| US6350445B1 | Method of treating cancer with a tumor cell line having modified cytokine expression | Chemistry; Metallurgy | 40 | Expired |
| US6033674A | Method of treating cancer with a tumor cell line having modified cytokine expression | Chemistry; Metallurgy | 40 | Expired |
| US7638122B2 | Stat3 antagonists and their use as vaccines against cancer | Chemistry; Metallurgy | 38 | Expired |
| US9005629B2 | Method for treating cancer with an antibody to CD223 protein | Emerging Cross-Sectional Technologies | 38 | Active |
| US5985290A | Purified pancreatic tumor cell lines and related compositions and method | Chemistry; Metallurgy | 36 | Expired |
| US7560540B2 | Nucleic acid encoding dendritic cell co-stimulatory molecules | Chemistry; Metallurgy | 35 | Expired |
| US8551481B2 | Anti-cancer vaccine composition comprising an anti-CD223 antibody and kit comprising an anti-cancer vaccine and an anti-CD223 antibody | Emerging Cross-Sectional Technologies | 34 | Active |
| US7030219B2 | B7-DC, Dendritic cell co-stimulatory molecules | Chemistry; Metallurgy | 34 | Expired |
| US6187306A | Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same | Human Necessities | 31 | Expired |
| US9770467B2 | Compositions and methods for cancer immunotherapy | Chemistry; Metallurgy | 29 | Active |
| US8053558B2 | Dendritic cell co-stimulatory molecules | Chemistry; Metallurgy | 26 | Active |
| US8053414B2 | Methods of using B7-DC molecules to induce or enhance an immune response | Chemistry; Metallurgy | 25 | Active |
| US6734013B2 | Use of multivalent chimeric peptide-loaded, MHC/Ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses | Chemistry; Metallurgy | 21 | Expired |
| US9308253B2 | Cancer immunotherapy | Human Necessities | 18 | Active |
| US10934356B2 | Checkpoint blockade and microsatellite instability | Chemistry; Metallurgy | 10 | Active |
| US11339219B2 | Checkpoint blockade and microsatellite instability | Chemistry; Metallurgy | 5 | Active |
| US11325974B2 | Checkpoint blockade and microsatellite instability | Chemistry; Metallurgy | 5 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.